Clinical Trial Update: Venetoclax, Ibrutinib, Prednisone, Obinutuzumab, and Revlimid (ViPOR) in Relapsed/Refractory B-cell Lymphoma [Phase 1, Phase 2]

View source ↗

Summary

This document outlines a Phase 1/2 clinical trial (ViPOR) evaluating a combination of venetoclax, ibrutinib, prednisone, obinutuzumab, and lenalidomide in relap…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Burkitt Lymphoma
• Diffuse Large B-cell Lymphoma
• Non-hodgkin Lymphoma

Drugs mentioned

• Gazyva (Obinutuzumab)
• IMBRUVICA (IBRUTINIB)
• PREDNISONE (Prednisone)
• Revlimid (lenalidomide)
• Venclexta (venetoclax)

Snippet

Sponsor: National Cancer Institute (NCI) | Conditions: Lymphoma, Non-Hodgkin Lymphoma | Phase 1, Phase 2 | Status: RECRUITING